Myelodysplastic Syndromes
Mostrando 25-36 de 74 artigos, teses e dissertações.
-
25. Screening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes
INTRODUCTION: Myelodysplastic syndromes encompass a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, refractory cytopenia and a tendency to progress toward acute myeloid leukemia. The accumulation of genetic alterations is closely associated with the progression of myelodysplastic syndromes toward ac
Clinics. Publicado em: 2011
-
26. Oncohematological diseases in the Vale do Paraíba, State of São Paulo: demographic aspects, prevalences and incidences
BACKGROUND: Based on the necessity of detailed information that supports effective strategies to improve cancer outcomes in the different regions of Brazil, the aims of this study were to report demographic aspects and to calculate the prevalence and incidence rates of oncohematological diseases in the region of Vale do Paraíba. METHODS: This is a multicent
Revista Brasileira de Hematologia e Hemoterapia. Publicado em: 2011
-
27. Avaliação do método de imunofenotipagem por citometria de fluxo no diagnóstico das doenças displásicas (SMD, LMA-relacionada à mielodisplasia, LMMC e LMMJ) em adultos e crianças / Evaluation of flow cytometric immunophenotyping analysis in diagnosis of dysplastic diseases (MDS, AML with myelodysplasia-related changes; CMML and JMML) in adults and children
As síndromes mielodisplásicas (SMD) se caracterizam por terem uma hematopoese displásica, citopenias e pelo risco de progressão para leucemia mielóide aguda. O diagnóstico baseia-se na clínica e nos achados citomorfológicos da medula óssea (MO) e citogenéticos. Na fase inicial ou quando a MO é hipocelular o diagnóstico é difícil e a citogenéti
Publicado em: 2011
-
28. Immunomodulatory effect of mesenchymal stem cells
Mesenchymal stem cells (MSC) are multipotential nonhematopoietic progenitor cells capable of differentiating into multiple mesenchymal tissues. MSC are able to reconstitute the functional human hematopoietic microenvironment and promote engraftment of hematopoietic stem cells. MSC constitutively express low levels of major histocompatibility complex-I molecu
Brazilian Journal of Medical and Biological Research. Publicado em: 2010-05
-
29. Estudo morfológico e por citogenética da medula óssea de portadores de síndrome mielodisplásica secundária no Serviço de Hematologia do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo / Morphological and cytogenetic bone marrow studies in patients with secondary myelodysplastic syndrome diagnosed at Department of Hematology of Clinical Hospital of São Paulo Medical School
As Síndromes mielodisplásicas (SMD) são doenças clonais da célula progenitora hematopoética, cursando com citopenias, medula óssea displástica e tendência à evolução para leucemia. As SMD secundárias estão associadas a fatores de risco como doenças congênitas (Anemia de Fanconi), doenças hematológicas adquiridas (aplasia medular, HPN), expo
Publicado em: 2010
-
30. Participação de proteínas tirosina quinase ativada por mitógenos (MAPKs) na indução do fator inibidor de leucemia (LIF) em células estromais da medula óssea de crianças com sindromes mielodisplásicas (SMD) / Participation of protein tyrosine kinase activated by mitógenos (MAPKs) in the induction of the inhibitory factor for leukemia (LIF) stromal cells in the bone marrow of children with Myelodysplastic Syndromes (MDS)
Em nosso trabalho anterior mostramos que dentre as citocinas analisadas, os níveis do mRNA de LIF nas células estromais pediátricas, de SMD e de SMD-LMA foram maiores quando comparados às células estromais de crianças saudáveis. No presente estudo, observamos um aumento tempo dependente nos níveis da proteína LIF após adição de SFB em todas as c�
Publicado em: 2008
-
31. Nodulos linfoides medulares em pacientes portadores de sindrome mielodisplasicas : incidencia, caracterização morfologica, imunohistoquimica e associação com criterios clinico-laboratoriais, progressão da doença e sobrevida
Myelodysplastic syndromes (MDS) are a heterogeneous group of c10na! disorders characterised by abnormalities in proliferation and maturation of haemopoietic precursors resulting in cytopenias and a preleukaemic state. Bone marrow lYffiphoid nodules (LN) are usually considered to be a physiological feature, closelyrelated to age. In patients with MDS their cl
Publicado em: 2001
-
32. Immune abnormalities in myelodysplastic syndromes.
The immune states of 52 patients with myelodysplastic syndromes classified according to the FAB criteria were studied. Serum electrophoresis and immunoelectrophoresis, direct Coombs test, and tests for organ and non-organ specific antibodies were performed. Twenty six patients had immunoglobulin abnormalities: six (11.5%) had monoclonal gammopathy; 17 (32.6%
-
33. Myelodysplastic syndromes.
The myelodysplastic syndromes are a heterogeneous group of hematopoietic stem cell disorders characterized by dysplastic and ineffective hematopoiesis and a varying risk of transformation to acute leukemia. Although the natural history of these syndromes is variable, several factors appear to be of prognostic importance, including the French-American-British
-
34. Granulocyte and monocyte surface membrane markers in the myelodysplastic syndromes.
The expression of lineage specific surface antigens on granulocytes and monocytes was quantitated using monoclonal antibodies in 16 healthy adults and 21 patients with myelodysplastic syndromes. In nine of 19 patients the granulocytes showed a decrease in myeloid or an increase in monocyte antigen expression or both. In 11 of 19 patients the monocytes showed
-
35. Platelet peroxidase deficiency in a case of myelodysplastic syndrome with myelofibrosis.
Morphological and functional abnormalities of the megakaryocytic series have been well described in myelodysplastic syndromes. Platelet peroxidase has always been demonstrated in abnormal megakaryocytes and early megakaryoblasts in such syndromes. We have studied a case of myelodysplastic syndrome with marked morphological abnormalities of megakaryocytes in
-
36. Erythrocyte autoantibodies, autoimmune haemolysis, and myelodysplastic syndromes.
Immunohaematological investigations were carried out in 46 patients with erythrocyte autoantibodies associated with myelodysplastic syndromes. Eight patients had refractory anaemia, 17 refractory anaemia with ring sideroblasts, 11 refractory anaemia with excess of blasts, four chronic myelomonocytic leukaemia, five refractory anaemia with excess of blasts in